AOD-9604 vs Tesamorelin: Fat-Loss Peptides

The Core Difference

AOD-9604 and Tesamorelin both trace back to growth hormone, but they approach fat loss from opposite ends of the system. AOD-9604 is a piece of the GH molecule that acts downstream, directly on fat cells. Tesamorelin works upstream, telling your pituitary to make more of your own growth hormone. That single distinction, downstream fragment versus upstream signal, drives every other difference between them: what happens to your IGF-1, how strong the human evidence is, and who each one fits.

AOD-9604 is the fat-burning fragment of human growth hormone, amino acids 176 to 191, isolated on its own. It was engineered to keep the effect GH has on fat metabolism while leaving out the parts that raise blood sugar, raise IGF-1, or drive tissue growth. In practice that means it can push fat cells to release stored fat without shifting your hormone levels. The trade-off is that its human clinical results have been modest, which we cover honestly below. Our full AOD-9604 guide Read nextAOD-9604: The Fat-Burning Fragment That Came From Growth HormoneGrowth hormone burns fat. It also raises blood sugar, swells joints, and can trigger abnormal growth. In 1993, an Australian biochemist isolated the 16 amino acids responsible for fat metabolism and nothing else. That fragment became AOD-9604.Read article walks through the mechanism and research in depth, and is AOD-9604 FDA approved Read nextIs AOD-9604 FDA Approved? 2026 Legal Status and AccessAOD 9604 completed Phase 2 clinical trials in Australia with 300+ patients. Development paused for efficacy, not safety.Read article covers its regulatory status.

Tesamorelin takes the upstream route. It is a stabilized analog of growth-hormone-releasing hormone (GHRH), engineered to resist enzyme breakdown so it lasts long enough to do its job. Rather than injecting GH or a GH fragment, it signals your pituitary to release a natural pulse of your own growth hormone. Because it raises GH, it also raises IGF-1, the downstream hormone GH produces. It is the only peptide in this category with FDA approval, and it has the strongest visceral-fat trial data of any option here. The full Tesamorelin guide Read nextTesamorelin 2026: FDA-Approved GHRH for Visceral FatMost peptides have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval.Read article goes deeper on the science and the trials.

Side-by-Side Comparison

AOD-9604: The Fat-Release Fragment

Growth hormone does many things: it builds tissue, raises IGF-1, influences blood sugar, and mobilizes fat. Researchers noticed that the fat-mobilizing effect lives in a specific stretch near the tail of the molecule. AOD-9604 is that stretch, amino acids 176 to 191, synthesized on its own with a small stabilizing tweak. The idea was to keep the fat-burning instruction and drop everything else.

In laboratory and animal work, the fragment behaved as designed. In obese mice, chronic treatment with AOD-9604 increased fat oxidation and reduced weight gain, without the adverse effect on insulin sensitivity seen with intact growth hormone. Mechanistic studies confirmed it stimulates lipolysis and does not compete for the GH receptor or trigger cell proliferation.

Ng FM et al., "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone," Hormone Research, 2000. View study

Heffernan MA et al., "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment," International Journal of Obesity, 2001. View study

Here is the honest limitation. When AOD-9604 moved into human trials, the results were modest. Early studies showed a small, statistically detectable weight-loss signal at some doses, but larger and longer trials did not separate clearly from placebo on their primary endpoints, and the drug was not pursued to approval for obesity. The mechanism is sound and the safety profile is favorable (the FDA granted GRAS status for the oral form), but the human efficacy story is a gentle nudge, not a dramatic transformation. That is why AOD-9604 is best thought of as targeted support rather than a heavy hitter, and why PeRx often pairs it with MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide .

That pairing is the AOD-9604/MOTS-c combo Read nextAOD 9604 + MOTS-c 2026: Metabolic Recomp Combo GuideOne peptide breaks down stored fat through beta-3 adrenergic lipolysis. The other reprograms cellular fuel efficiency through AMPK activation. Two angles on the same metabolic problem, in a single pre-mixed vial.Read article . AOD-9604 works on releasing stored fat while MOTS-c, a mitochondrial-derived peptide, activates AMPK to improve how your cells process fuel. The two mechanisms sit in different places, so the combo covers fat release and metabolic flexibility in one vial. You can read more on the AOD-9604 product page Explore PeRxAOD-9604Pure Fat Burning PeptideView peptide or the combo product page Explore PeRxAOD 9604/MOTS-cFat Burning + Metabolic ResetView peptide .

Tesamorelin: The FDA-Approved GHRH Analog

Tesamorelin sits at the other end of the system. Instead of delivering a fat-burning fragment, it delivers a signal. It binds GHRH receptors in the pituitary and prompts the gland to release a natural pulse of your own growth hormone. Because it raises GH, IGF-1 rises with it, which is a feature of how it works rather than a side detail. That is the central contrast with AOD-9604: Tesamorelin deliberately turns up the growth-hormone axis, while AOD-9604 leaves it alone.

What sets Tesamorelin apart clinically is where the fat loss lands. It drives lipolysis specifically in visceral adipose tissue, the deep belly fat that wraps around the organs and is most tied to metabolic risk, while largely sparing subcutaneous fat and lean mass. That specificity is backed by the strongest human evidence in this category. Two Phase 3, randomized, double-blind, placebo-controlled trials enrolled 816 patients and measured visceral fat by CT scan. Visceral fat dropped by roughly 15% over 26 weeks, with improved triglycerides and preserved lean mass.

Falutz J et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, 2007. View study

Later research extended the picture to the liver. A multicenter trial published in The Lancet HIV in 2019 found that Tesamorelin reduced hepatic (liver) fat, with a meaningful share of treated patients normalizing liver fat compared with placebo. This is the kind of organ-level, CT-verified data that AOD-9604 never generated, and it is the reason Tesamorelin is the reference point for visceral fat.

Stanley TL et al., "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial," The Lancet HIV, 2019. View study

Tesamorelin was FDA-approved in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Off-label use for general visceral fat is prescribed by licensed providers and compounded at US pharmacies. It is a single daily subcutaneous injection on a provider-determined schedule. See the Tesamorelin product page Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide for how PeRx ships it.

Which One Fits You?

The decision is not really AOD-9604 versus Tesamorelin as better or worse. It is a question of what you want to happen to your hormones and how much clinical evidence you want behind the choice. If your goal is targeted fat support with your GH axis left alone, AOD-9604 (or the AOD-9604/MOTS-c combo) is the non-hormonal route. If your priority is visceral fat and the strongest trial pedigree, Tesamorelin is the reference standard. Your provider makes the call during your assessment, weighing your history, labs, and goals. If you are comparing GH-raising options more broadly, our Tesamorelin vs CJC-1295/Ipamorelin guide Read nextTesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs DualTesamorelin is the only FDA-approved GH peptide. CJC-1295/Ipamorelin is the most popular compounded GH stack.Read article covers the other side of that family.

AOD-9604 vs Tesamorelin: Common Questions